ChemicalBook > Product Catalog >Biochemical Engineering >Nucleoside drugs >Deoxynucleotides and their analogs >Zalcitabine


Zalcitabine Suppliers list
Company Name: Mainchem Co., Ltd.
Tel: +86-0592-6210733
Products Intro: Product Name:Zalcitabine
Company Name: Chongqing Chemdad Co.,Ltd
Tel: +86-19923101450
Products Intro: Product Name:2',3'-Dideoxycytidine
Company Name: Nanjing Baifuli Technology Co., Ltd.
Tel: +86-15335185688
Products Intro: Product Name:Zalcitabine
Purity:98% Package:On Request
Company Name: career henan chemical co
Tel: +86-371-86658258
Products Intro: Product Name:Zalcitabine
Purity:98% Package:1KG;2USD
Company Name: Chemwill Asia Co.,Ltd.
Tel: 86-21-51086038
Products Intro: CAS:7481-89-2
Purity:0.99 Package:5KG;1KG;25KG PRICE quotation Remarks:Factory stock, quality assurance, price concessions

Lastest Price from Zalcitabine manufacturers

  • Zalcitabine
  • US $2.00 / KG
  • 2019-07-06
  • CAS:7481-89-2
  • Min. Order: 1KG
  • Purity: 98%
  • Supply Ability: 1ton
Zalcitabine Basic information
Product Name:Zalcitabine
Product Categories:-;Pharmaceutical Raw Materials;Miscellaneous Biochemicals;Antivirals for Research and Experimental Use;Biochemistry;Chemical Reagents for Pharmacology Research;Nucleosides and their analogs;Nucleosides, Nucleotides & Related Reagents;Bases & Related Reagents;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals;Other APIs;Inhibitors
Mol File:7481-89-2.mol
Zalcitabine Structure
Zalcitabine Chemical Properties
Melting point 217-218 °C(lit.)
alpha D25 +81° (c = 0.635 in water)
Boiling point 350.9°C (rough estimate)
density 1.2605 (rough estimate)
refractive index 78 ° (C=0.5, H2O)
storage temp. 2-8°C
form powder
color colorless
Water Solubility 5-10 g/100 mL at 19 ºC
Merck 14,10109
BRN 654956
Stability:Stable. Combustible. Incompatible with strong oxidizing agents.
CAS DataBase Reference7481-89-2(CAS DataBase Reference)
EPA Substance Registry SystemCytidine, 2',3'-dideoxy-(7481-89-2)
Safety Information
Hazard Codes Xn,C
Risk Statements 40-36/37-34
Safety Statements 22-36-45-36/37/39-27-26
WGK Germany 3
RTECS HA3870000
Hazardous Substances Data7481-89-2(Hazardous Substances Data)
MSDS Information
DDC English
SigmaAldrich English
ALFA English
Zalcitabine Usage And Synthesis
DescriptionZalcitabine is an orally active dideoxynucleoside andog for combination use with zidovudine in advanced HIV infection and also as monotherapy for AIDS patients who cannot tolerate or have not responded to zidovudine. It has a similar mechanism of action (inhibition of reverse transcriptase) to didanosine. Like didanosine, its side effect profile includes peripheral neuropathy. Unlike zidovudine, zalcitabine does not cause bone marrow suppression.
Chemical PropertiesWhite to Off-White Cyrstalline Powder
OriginatorNational Cancer Institute (NIH) (U.S.A.)
UsesA pyrimidine nucleoside analogue with antiviral activity
Usesammonia detoxicant, diagnostic aid
DefinitionChEBI: A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.
IndicationsZalcitabine (ddC, Hivid) is a cytidine analogue active against HIV-1, HIV-2, and hepatitis B virus. It is used for the treatment of HIV infection in adults and asymptomatic children as part of a multidrug regimen. It may be less effective than the other nucleoside inhibitors and is used less frequently.
Brand nameHivid (Roche).
General DescriptionZalcitabine, 2',3'-dideoxycytidine or ddCyd, is an analog ofcytosine that demonstrates activity against HIV-1 and HIV-2,including strains resistant to AZT. The potency (in peripheralblood mononuclear cells) is similar to that of AZT, but thedrug is more active in populations of monocytes andmacrophages as well as in resting cells.
The oral bioavailability of zalcitabine is over 80% in adultsand less in children.The major dose-limiting side effect isperipheral neuropathy, characterized by pain, paresthesias,and hypesthesia, beginning in the distal lower extremities.These side effects are typically evident after several months oftherapy with zalcitabine. A potentially fatal pancreatitis is anothertoxic effect of treatment with ddC. The drug has beenapproved for the treatment of HIV infection in adults with advanceddisease who are intolerant to AZT or who have diseaseprogression while receiving AZT. ddC is combined with AZTfor the treatment of advanced HIV infection.
General DescriptionWhite crystalline powder. Odorless.
Air & Water ReactionsWater soluble.
Reactivity ProfileZalcitabine may be sensitive to prolonged exposure to light.
Fire HazardFlash point data for Zalcitabine are not available; however, Zalcitabine is probably combustible.
PharmacologyPeripheral neuropathy occurs in up to 50% of patients taking zalcitabine. Stomatitis, esophageal ulceration, hepatotoxicity, rash, and pancreatitis may occur. Zalcitabine should be used with caution in individuals with a history of pancreatitis, liver disease, or alcohol abuse. Dosage adjustment is necessary for individuals with renal impairment. Zalcitabine should not be used in combination with didanosine, lamivudine, or stavudine.
Zalcitabine Preparation Products And Raw materials
Raw materialsAmmonia-->Palladium-->Hydrogen-->Acetyl bromide-->Cytidine
Tag:Zalcitabine(7481-89-2) Related Product Information
5'-O-Dimethoxytrityl-N-benzoyl-desoxycytidine (+)-3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)cytidine N4-Acetylcytidine Cytidine Deoxynucleotide Cytarabine 5-Azacytidine Floxuridine Cytidine-5'-triphosphate disodium salt dihydrate Zalcitabine 1-beta-D-Arabinofuranosylcytosine hydrochloride Neosperidin dihydrochalcone DNA, SINGLE STRANDED, IMM. ON CELLULOSE, FROM CALF THYMUS* Deoxidizer Fluorocytosine Citiolone Dideoxyinosine Cytosine